Biosyent (RX) Releases Earnings Results, Meets Expectations
Biosyent (CVE:RX) posted its quarterly earnings results on Wednesday. The company reported C$0.10 earnings per share for the quarter, meeting the consensus estimate of C$0.10, Morningstar.com reports. The firm had revenue of C$5.90 million for the quarter. Biosyent had a return on equity of 25.90% and a net margin of 23.96%.
Biosyent (CVE RX) traded down C$0.19 during trading hours on Friday, reaching C$9.51. The company had a trading volume of 100 shares, compared to its average volume of 11,407. The firm has a market capitalization of $139.88, a price-to-earnings ratio of 28.82 and a beta of 1.11. Biosyent has a 52-week low of C$7.30 and a 52-week high of C$11.00.
BioSyent Inc is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc, acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business.
Receive News & Ratings for Biosyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent and related companies with MarketBeat.com's FREE daily email newsletter.